Survival analysis in patients treated with low-dose VenAza or intensive chemotherapy. (A) The VenAza group showed comparable OS to ICH (median OS, 10.1 vs 9.0 months; P = .097), (B) and significantly longer relapse-free survival (not reached vs 6.2 months; P = .017). (C) No significant difference was observed in event-free survival (6.3 vs 3.4 months; P = .266). Survival analysis was performed in R using the survival and survminer packages. No image editing was applied beyond global formatting via ggplot2.